| 1.8 0.42 (30.43%) | 07-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.05 | 1-year : | 9.35 |
| Resists | First : | 5.18 | Second : | 8.01 |
| Pivot price | 1.47 |
|||
| Supports | First : | 0.61 | Second : | 0.51 |
| MAs | MA(5) : | 2.94 |
MA(20) : | 1.27 |
| MA(100) : | 0.96 |
MA(250) : | 2.48 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 18.6 |
D(3) : | 40.7 |
| RSI | RSI(14): 51.5 |
|||
| 52-week | High : | 13.07 | Low : | 0.61 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ZYBT ] has closed below upper band by 46.0%. Bollinger Bands are 1243.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.07 - 2.08 | 2.08 - 2.1 |
| Low: | 1.54 - 1.55 | 1.55 - 1.56 |
| Close: | 1.74 - 1.76 | 1.76 - 1.78 |
Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry. Additionally, its product range encompasses inoculations for canines. Beyond its domestic reach, the firm also distributes its offerings to international markets, notably exporting to Vietnam, Pakistan, and Egypt. Established in 2004, this enterprise bases its principal operations in Jilin, China, and operates as a subsidiary entity of Securingium Holding Limited.
Thu, 23 Jul 2026
Zhenfa Han Net Worth (2026) - GuruFocus
Wed, 22 Jul 2026
Zhengye Biotechnology Stock Plunges Following 322% Rally In Volatile Reversal - Benzinga
Tue, 21 Jul 2026
Zhengye Biotechnology Says No Material Events Behind Unusual Trading Activity (NASDAQ:ZYBT) - Yahoo Finance
Tue, 21 Jul 2026
ZYBT Stock Whipsaws After Parabolic Spike Draws Day Traders - StocksToTrade
Tue, 21 Jul 2026
Zhengye Biotechnology addresses unusual trading activity By Investing.com - Investing.com Nigeria
Tue, 21 Jul 2026
Zhengye Biotechnology Holding Limited Says It Is Unaware of Material Non-Public Information Amid Unusual Trading Activity - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 47 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 16.1 (%) |
| Held by Institutions | 1.1 (%) |
| Shares Short | 44 (K) |
| Shares Short P.Month | 30 (K) |
| EPS | -0.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.91 |
| Profit Margin | -60 % |
| Operating Margin | -77.1 % |
| Return on Assets (ttm) | -9.5 % |
| Return on Equity (ttm) | -25.2 % |
| Qtrly Rev. Growth | -41 % |
| Gross Profit (p.s.) | 0.5 |
| Sales Per Share | 2.45 |
| EBITDA (p.s.) | -0.95 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 13 (M) |
| Levered Free Cash Flow | 40 (M) |
| PE Ratio | -8.01 |
| PEG Ratio | 0 |
| Price to Book value | 1.93 |
| Price to Sales | 0.71 |
| Price to Cash Flow | 6.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|